Tyme Technologies, Inc.
(NASDAQ : TYME)

( )
TYME After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -1.31%43.000.9%$1131.01m
ABBVAbbVie, Inc. -0.30%107.401.9%$1036.13m
JNJJohnson & Johnson -0.16%162.910.7%$988.77m
MRKMerck & Co., Inc. -0.11%73.280.7%$937.00m
LLYEli Lilly & Co. -2.07%221.721.1%$592.16m
BMYBristol-Myers Squibb Co. 0.02%59.851.0%$591.86m
AZNAstraZeneca Plc -1.86%57.631.0%$345.66m
NVSNovartis AG -0.34%82.310.2%$159.64m
CRVSCorvus Pharmaceuticals, Inc. -10.17%6.890.7%$147.73m
GSKGlaxoSmithKline Plc -1.14%38.060.2%$133.73m
RGENRepligen Corp. -7.09%285.576.8%$119.88m
RPRXRoyalty Pharma Plc -1.43%36.620.1%$118.91m
SNYSanofi -0.46%47.900.2%$117.35m
VTRSViatris, Inc. -0.87%13.700.0%$115.06m
APLSApellis Pharmaceuticals, Inc. 0.20%35.130.0%$104.57m

Company Profile

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.